ImmunityBio

Outsmart Your Disease™ ImmunityBio, Inc. (formerly NantKwest, Inc.)

is a leading late-stage cell & immunotherapy company activating both the innate (natural killer cell and macrophage) and adaptive (T cell) immune system to help strengthen and potentially enabling it to outsmart the disease and eliminate rogue or infected cells. Over the last two decades, our founder and Executive Chairman Dr. Patrick Soon-Shiong has investigated mechanisms to activate the immune

system to attack tumors that can otherwise evade and escape the body’s defense mechanisms. After inventing the world’s first protein nanoparticle drug, Abraxane, Dr. Soon-Shiong turned his focus to the next generation of immunotherapies. ImmunityBio was founded in 2014 to create innovative immunotherapies that address serious unmet needs in oncology and infectious diseases. "At ImmunityBio, we envision a day when we no longer fear cancer but are able to conquer it, thanks to the biological wonder that is the human immune system. Our scientists are working to develop remarkable new therapies that harness that inherent power by amplifying both branches of the immune system, attacking cancerous or infected cells today while building immunological memory for tomorrow. The goal: to reprogram the patient’s immune system and treat the host rather than just the disease." -Dr. Patrick Soon-Shiong, Executive Chairman. Since then we have progressed into a late-stage clinical company with more than 40 Phase I, II, or III clinical trials (company-sponsored and investigator-initiated) in development across 19 indications in solid and liquid cancers and infectious diseases. Our proprietary natural killer cell platform can be easily expanded, genetically modified, and cryopreserved and offers multiple modes of cytotoxicity. Our lead antibody cytokine fusion protein, Anktiva, has received FDA Breakthrough Therapy designation for one of the most common and difficult to treat types of bladder cancer (BCG-unresponsive non-muscle invasive bladder cancer). Our work is led by a senior team with highly complementary and broad expertise across novel scientific areas including genomics and proteomics, monoclonal antibodies, fusion proteins, vaccines, and autologous and allogeneic cell therapy, based on experiences at companies ranging from biotech startups to large commercial pharmaceutical enterprises.

07/21/2025

Our scientists translate rigorous immunology research into innovative cell- and immune-based therapies, working every day to expand treatment options and improve outcomes for patients.

07/15/2025

According to the American Cancer Society, lung cancer accounts for nearly 1 in 5 cancer deaths in the United States. ImmunityBio is focused on developing therapies that address this ongoing health challenge. Read more: https://immunitybio.com/non-small-cell-lung-cancer/

07/10/2025

Our scientists are working to develop remarkable new therapies that harness the body's inherent power by amplifying both the innate and adaptive branches of the immune system, facilitating the attack and elimination of cancerous or infected cells today while building immunological memory for tomorrow. Learn more: https://immunitybio.com/pipeline/

07/08/2025

Today, we announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted the first marketing approval outside the United States for this novel lymphocyte-stimulating agent, ANKTIVA® (nogapendekin alfa inbakicept-pmln), in combination with Bacillus Calmette-Guérin (BCG) for the treatment of certain bladder cancer patients. Learn more: https://immunitybio.com/uk-mhra-approves-immunitybios-anktiva-plus-bcg-for-bcg-unresponsive-non-muscle-invasive-bladder-cancer-carcinoma-in-situ/

07/04/2025

On this Independence Day, we recognize the sacrifices made for our freedom and the strength of the communities that continue to move our nation forward. The team at ImmunityBio wishes you a safe and happy holiday.

07/02/2025

Bladder cancer recurrence is a reality for nearly half of patients with non-muscle invasive disease. ImmunityBio is advancing immunotherapy-based research to help the body's own defenses recognize and fight cancer. Learn more: https://immunitybio.com/bladder-cancer/

06/26/2025

Join us in transforming the future of cancer treatment. ImmunityBio is advancing innovative therapies that bring new hope to patients facing some of the most challenging cancers. We're looking for passionate, mission-driven individuals to grow with us.

Be a part of something bigger. Explore open positions and apply today: https://immunitybio.com/careers/

06/24/2025

Lymphopenia is a serious condition affecting many patients with cancer - especially those undergoing chemotherapy or radiation. It can leave the immune system compromised and limit the body's ability to fight illness.

We're working to address this challenge through our science and ongoing clinical research with a goal of improving outcomes by enhancing immune recovery.

06/23/2025

We are happy to share that, as a proud sponsor of the SITC event at Buddy Guy’s Legends, we helped raise over $60,000 through the Forward Fund. These funds will directly support the programs, awards, and grants that advance the professional development of investigators, ensuring a bright future for innovation in immunotherapy.

06/19/2025

Annually, over 230,000 people in the United States are diagnosed with lung cancer, with the majority facing non-small cell lung cancer (NSCLC). We're working to enhance the activity of NK and T cells, empowering the immune system to better combat NSCLC. Learn more about our approach: https://immunitybio.com/non-small-cell-lung-cancer/

06/16/2025

"Smart therapies for difficult diseases" isn't just a phrase - it is the foundation of everything we do. At ImmunityBio, we're working to transform how cancer is treated by designing therapies that not only target disease, but restore the body's natural ability to fight it. View our pipeline: https://immunitybio.com/pipeline/

06/13/2025

At ImmunityBio, our commitment to innovation drives us to explore new frontiers in medicine. From addressing genetic disorders like Lynch syndrome to tackling complex cancers such as bladder cancer, we are dedicated to making a meaningful impact. Join us in our journey to transform the future of healthcare by viewing our pipeline: https://immunitybio.com/pipeline/

Address

El Segundo, CA

Telephone

+18446965235

Website

http://www.immunitybio.com/

Alerts

Be the first to know and let us send you an email when ImmunityBio posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to ImmunityBio: